Article

Today, first-line treatments for multiple sclerosis include injectable
immunomodulators - some of which have been on the market for nearly 25 years - as
well as teriflunomide and dimethyl fumarate, which are more recent, but have
opened the way for oral treatments. These drugs are considered similar in
effectiveness, and their safety and side-effect profiles are generally
reassuring. These treatments have been associated with a reduction in
radiological and clinical disease activity, and a positive effect on patient
quality of life, especially when introduced early in the disease process. This
article will discuss data on first-line treatments currently available in France,
their effectiveness and safety, and their place in pediatric patients and in woman who plan to become pregnant.
CI - Copyright (c) 2018 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS